close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorGezondheidszorg

8.35 -7.02

Strong Buy

Prijsupdate 13 feb 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.3

Max

8.61

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+94.29% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

116M

Vorige openingsprijs

15.37

Vorige sluitingsprijs

8.35

Nieuwssentiment

By Acuity

60%

40%

296 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 feb 2026, 23:21 UTC

Acquisities, Fusies, Overnames

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

DJ

Lezen

15 feb 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

DJ

Lezen

15 feb 2026, 23:40 UTC

Marktinformatie

Gold Falls on Possible Position Adjustments -- Market Talk

DJ

Lezen

15 feb 2026, 23:06 UTC

Winsten

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

DJ

Lezen

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

DJ

Lezen

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

DJ

Lezen

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

DJ

Lezen

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

DJ

Lezen

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

DJ

Lezen

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

DJ

Lezen

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Shareholders to Receive A$5.20/Share in Cash

DJ

Lezen

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

DJ

Lezen

15 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

BlueScope CEO Tania Archibald Speaking on a Call With Media

DJ

Lezen

15 feb 2026, 22:17 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

DJ

Lezen

15 feb 2026, 22:16 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

DJ

Lezen

15 feb 2026, 22:14 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

DJ

Lezen

15 feb 2026, 22:14 UTC

Acquisities, Fusies, Overnames

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

DJ

Lezen

15 feb 2026, 20:48 UTC

Winsten

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

DJ

Lezen

15 feb 2026, 20:47 UTC

Winsten

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

DJ

Lezen

15 feb 2026, 20:46 UTC

Winsten

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

DJ

Lezen

15 feb 2026, 20:45 UTC

Winsten

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

DJ

Lezen

15 feb 2026, 20:44 UTC

Winsten

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

DJ

Lezen

15 feb 2026, 20:44 UTC

Winsten

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

DJ

Lezen

15 feb 2026, 20:43 UTC

Winsten

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

DJ

Lezen

15 feb 2026, 20:42 UTC

Winsten

BlueScope Net Debt A$2.2 Million at Dec. 31

DJ

Lezen

15 feb 2026, 20:42 UTC

Winsten

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

DJ

Lezen

15 feb 2026, 20:41 UTC

Winsten

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

DJ

Lezen

15 feb 2026, 20:40 UTC

Winsten

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

DJ

Lezen

15 feb 2026, 20:40 UTC

Winsten

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

DJ

Lezen

15 feb 2026, 20:39 UTC

Winsten

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

94.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD  94.29%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

296 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,040.03

↑ +0.29%

JNJ

Johnson and Johnson

243.3

↓-0.53%

ABBV

AbbVie Inc

231.41

↑ +1.75%

NVS

Novartis AG

162.81

↑ +1.21%

MRK

Merck & Co Inc.

121.33

↑ +1.83%
help-icon Live chat